Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.

Autor: Gui G; Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA.; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Ravindra N; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Hegde PS; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Andrew G; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Mukherjee D; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Wong Z; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Auletta JJ; Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN, USA.; The Ohio State University College of Medicine, Columbus, OH, USA., El Chaer F; University of Virginia, Charlottesville, VA, USA., Chen EC; Dana-Farber Cancer Institute, Boston, MA, USA., Chen YB; Massachusetts General Hospital, Boston, MA, USA., Corner A; Bio-Rad Laboratories, Pleasanton, CA, USA., Devine SM; Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN, USA., Iyer SG; Columbia University Irving Medical Center, New York, NY, USA., Jimenez Jimenez AM; Sylvester Comprehensive Cancer Center, Miami, FL, USA., De Lima MJG; The Ohio State University College of Medicine, Columbus, OH, USA., Litzow MR; Mayo Clinic, Rochester, MN, USA., Kebriaei P; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Saber W; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA., Spellman SR; Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN, USA., Zeger SL; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Page KM; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA., Dillon LW; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. laura.dillon2@nih.gov., Hourigan CS; Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA. hourigan@vt.edu.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Nov 06. Date of Electronic Publication: 2024 Nov 06.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia.

Autor: Dillon LW; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Gui G; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Ravindra N; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Andrew G; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Mukherjee D; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Wong ZC; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Huang Y; Invivoscribe, San Diego, California., Gerhold J; Invivoscribe, San Diego, California., Holman M; Invivoscribe, San Diego, California., D'Angelo J; Invivoscribe, San Diego, California., Miller J; Invivoscribe, San Diego, California., Higgins J; TwinStrand Biosciences, Seattle, Washington., Salk JJ; TwinStrand Biosciences, Seattle, Washington.; University of Washington School of Medicine, Seattle., Auletta JJ; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.; The Ohio State University College of Medicine, Columbus., El Chaer F; University of Virginia, Charlottesville., Devine SM; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota., Jimenez-Jimenez AM; Sylvester Comprehensive Cancer Center, Miami, Florida., De Lima MJG; The Ohio State University College of Medicine, Columbus., Litzow MR; Mayo Clinic, Rochester, Minnesota., Kebriaei P; The University of Texas MD Anderson Cancer Center, Houston., Saber W; Medical College of Wisconsin, Milwaukee.; National Marrow Donor Program, Minneapolis, Minnesota., Spellman SR; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.; National Marrow Donor Program, Minneapolis, Minnesota., Zeger SL; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland., Page KM; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.; Medical College of Wisconsin, Milwaukee., Hourigan CS; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.; Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Aug 01; Vol. 10 (8), pp. 1104-1110.

Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.

Autor: Ravindra N; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Dillon LW; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Gui G; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Smith M; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Gondek LP; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Jones RJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Corner A; Bio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA, USA., Hourigan CS; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. hourigan@nih.gov.; Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD, USA. hourigan@nih.gov., Ambinder AJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Mar; Vol. 59 (3), pp. 428-430. Date of Electronic Publication: 2024 Jan 05.

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.

Autor: Versluis J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Saber W; Medical College of Wisconsin, Milwaukee, WI., Tsai HK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Gibson CJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dillon LW; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Mishra A; Moffitt Cancer Center, Tampa, FL., McGuirk J; University of Kansas Cancer Center, Kansas City, KS., Maziarz RT; Oregon Health and Science University, Portland, OR., Westervelt P; Washington University in Saint Louis, Saint Louis, MO., Hegde P; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Mukherjee D; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Martens MJ; Medical College of Wisconsin, Milwaukee, WI., Logan B; Medical College of Wisconsin, Milwaukee, WI., Horowitz M; Medical College of Wisconsin, Milwaukee, WI., Hourigan CS; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.; Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD., Nakamura R; City of Hope National Medical Center, Duarte, CA., Cutler C; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Lindsley RC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Oct 01; Vol. 41 (28), pp. 4497-4510. Date of Electronic Publication: 2023 Aug 22.

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia.

Autor: Gui G; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Dillon LW; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Ravindra N; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Hegde PS; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Andrew G; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Mukherjee D; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Wong Z; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD., Auletta J; Center for International Blood and Marrow Transplant Research, Minneapolis, MN.; The Ohio State University College of Medicine, Columbus, OH., El Chaer F; University of Virginia, Charlottesville, VA., Chen E; Dana-Farber Cancer Institute, Boston, MA., Chen YB; Massachusetts General Hospital, Boston, MA., Corner A; Bio-Rad Laboratories, Pleasanton, CA., Devine SM; Center for International Blood and Marrow Transplant Research, Minneapolis, MN., Iyer S; Columbia University Irving Medical Center, New York, NY., Jimenez Jimenez AM; Sylvester Comprehensive Cancer Center, Miami, FL., De Lima MJG; The Ohio State University College of Medicine, Columbus, OH., Litzow MR; Mayo Clinic, Rochester, MN., Kebriaei P; The University of Texas MD Anderson Cancer Center, Houston, TX., Spellman SR; Center for International Blood and Marrow Transplant Research, Minneapolis, MN.; National Marrow Donor Program, Minneapolis, MN., Zeger SL; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Page KM; Center for International Blood and Marrow Transplant Research, Minneapolis, MN.; Medical College of Wisconsin, Milwaukee, WI., Hourigan CS; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.; Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD.

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2023 Aug 01. Date of Electronic Publication: 2023 Aug 01.